Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

Clinical trial NCT07490275 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07490275
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory/Relapsed Systemic Lupus Erythematosus Refractory / Relapsed / Progressive Systemic Sclerosis Refractory / Relapsing / Progressive Inflammatory Myopathy Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Refractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia

Start date: 2026-07-01
Primary completion: 2028-12-31
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.